Last updated on December 2019

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)


Brief description of study

The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab intravenous (Dara-IV) to evaluate daratumumab retreatment.

Detailed Study Description

For relapsed or refractory multiple myeloma, the treatment is determined on an individual basis. Common standard of care regimens use either a proteasome inhibitor (PI) or an immunomodulatory agent (IMiD) in combination with dexamethasone with or without a monoclonal antibody (mAb) such as daratumumab. After relapse from PIs or IMiDs, patients are often retreated with drugs that have same mechanism of action to which they have been sensitive. The disease becomes refractory and all effective treatment options are exhausted. Daratumumab is a human IgG1 mAb that binds with high affinity to unique epitope on cluster of differentiation 38 (CD38) and attacks tumor cells that overexpress CD38. Study is to determine the efficacy of Dara-SC in combination with carfilzomib and dexamethasone (DKd) in adult participants with relapsed refractory MM who had 1 or 2 prior line(s) of treatment including a line containing Dara-IV to evaluate daratumumab retreatment. The MM treatment is determined on an individual basis where patient's age, prior therapy, bone marrow function, co-morbidities, patient preference and time to relapse are considered. Common standard of care regimens use either PI or an IMiD in combination with dexamethasone with or without a mAb. It is a targeted immunotherapy that attacks tumor cells that overexpress CD38, a transmembrane glycoprotein, in a variety of hematological malignancies including multiple myeloma. The study will be conducted in 3 phases: Screening (28 days), Treatment, and Follow-Up. Assessments like chest X-ray, spirometry test, electrocardiogram (ECG), will be performed during Screening phase. During the Treatment Phase, participants will be randomized to receive Kd or DKd. Efficacy assessments like bone marrow examination will be performed. Follow-up will continue until the end of study.

Clinical Study Identifier: NCT03871829

Find a site near you

Start Over

Cleveland Clinic Main Campus

Cleveland, OH United States
  Connect »

Millennium Oncology

Houston, TX United States
  Connect »

Medical College Of Wisconsin

Milwaukee, WI United States
  Connect »

ZNA Stuivenberg

Antwerpen, Belgium
  Connect »

UZ Gent

Gent, Belgium
  Connect »

CEHON

Salvador, Brazil
  Connect »

Hotel Dieu

Nantes, France
  Connect »

Schwarzwald-Baar Klinikum

Villingen-Schwenningen, Germany
  Connect »

VUMC

Amsterdam, Netherlands
  Connect »

Hosp. Univ. de Canarias

San Cristóbal de La Laguna, Spain
  Connect »

Hosp. Univ. de Canarias

San Cristóbal de La Laguna, Spain
  Connect »

Mayo Clinic - Rochester

Rochester, MN United States
  Connect »

Hosp. Univ. de Canarias

San Cristóbal de La Laguna, Spain
  Connect »

Hosp. Univ. de Canarias

San Cristóbal de La Laguna, Spain
  Connect »

Emergency Hospital of Dzerzhinsk

Dzerzhinsk, Russian Federation
  Connect »

Nizhniy Novgorod Region Clinical Hospital

Nizhny Novgorod, Russian Federation
  Connect »

Oncological dispensary #2

Sochi, Russian Federation
  Connect »

Hosp. Univ. de Canarias

San Cristóbal de La Laguna, Spain
  Connect »